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Abstract  
 
Cell division, in addition to an accurate transmission of genetic information to daughter 
cells, also requires the temporal and spatial coordination of several biological processes 
without which cell division would not be feasible. These processes include the temporal 
coordination of DNA replication and chromosome segregation, regulation of nuclear 
envelope disassembly and assembly, chromatin condensation and Golgi fragmentation 
for its redistribution into daughter cells, among others. However, little is known 
regarding regulatory proteins and signalling pathways that might participate in the 
coordination of all these different biological functions. Such regulatory players should 
directly have a role in the processes leading to cell division. VRK1 (Vaccinia-related 
kinase 1) is an early response gene required for cyclin D1 expression, regulates p53 by a 
specific Thr18 phosphorylation, controls chromatin condensation by histone 
phosphorylation, nuclear envelope assembly by phosphorylation of BANF1, and 
participates in signalling required for Golgi fragmentation late in the G2 phase. We 
propose that VRK1, a Ser-Thr kinase, might be a candidate to play an important 
coordinator role in these cell division processes as part of a novel signalling pathway.  
 
 
1. VRK1 and mitotic processes. 
  
Cell division is a complex process requiring the synchronization of multiple functions in 
addition to a correct DNA replication and chromosome segregation in mitosis [1]. 
Several cellular processes have to be coordinated to generate two daughter cells. These 
include nuclear membrane disassembly and reassembly, chromatin condensation, 
mitotic spindle assembly and disassembly, centrosome duplication, cyclin gene 
expression, Golgi fragmentation, and setting up DNA damage response pathways in a 
readiness state to intervene if necessary by acting on mitotic checkpoints. All of them 
need to be coordinated, otherwise cell division will not be feasible, but so far no 
candidate regulatory protein or signalling pathway has been clearly identified for this 
role. Such coordinator protein must be able to receive and integrate signals with 
different origins such as growth factors or cell damage. This protein must also have 
downstream targets that have to be implicated and be essential in several of the 
processes to be regulated, in which this protein will also function as a master 
coordinator. To perform such coordinator role, a kinase would be the most suitable 
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candidate since kinases are able to receive input signals from different origins and, their 
action is reversible and they  can have multiple substrates. These substrates would have 
to include key components of the different processes targeted and involved in cell 
division, many of which are known to be regulated by different kinases either being 
directly phosphorylated or requiring the participation of a kinase for their function.  
In this context we hypothesize that the kinase VRK1 is a candidate to perform 
such a coordinating role, based on current data available, since it is required to exit G0 
and enter in the G1 phase of cell cycle [2], has several targets affecting progression of 
G1 phase  [2, 3]and participates in nuclear envelop dynamics [4], chromatin 
condensation [5] and Golgi fragmentation [6] (Fig. 1). The functional position of such 
coordinator protein affecting several processes suggests that this gene is not likely to be 
mutated in cancer, since its consequences are likely to have catastrophic and cells will 
not be viable, in case of loss of function. In a large study searching for kinase mutations 
in human cancer, VRK1 is not mutated, consistent with such a role [7].  
 
2. The human VRK1 Ser-Thr kinase 
In the human kinome there is an isolated  and early divergent branch from the 
CK1 family, the VRK (Vaccinia-related kinase) family of  Ser-Thr kinases, which is 
composed of three members in mammals [8], and of which only two, VRK1 and VRK2 
are active as kinases [9, 10]. These VRK proteins have aminoacid substitutions in key 
residues that are conserved in almost all other kinases in the human kinome [8]. VRK1 
consists of 396 aminoacids with an N-terminal active kinase domain.  Its C-terminal 
region has a nuclear localization signal, and a basic-acid-basic motif (BAB motif) of 
unknown function. VRK1 does not have any additional distinctively known feature that 
might be present in other proteins [11]. The VRK1 protein is mostly located in the 
nucleus, but it is also present in Golgi and some cytosolic vesicles [6, 12], and the 
regulation of its subcellular distribution is not yet known. 
 The VRK family has a unique ortholog gene in C. elegans, Vrk-1[13] and D. 
melanogaster, NHK-1 (nucleosomal histone kinase-1) [14, 15]. The homology is 
restricted to their kinase domain, and all of them have C-terminal regions which are 
unrelated among them, and with few known characteristics. These structural differences 
suggest that they might have common kinase substrates, but probably different 
regulation or protein interactions. No ortholog has been identified in yeasts. This 
situation resembles that of the p53 protein, which is not present in yeasts and that also 
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appeared late in evolution with a single member in lower eukaryotes (invertebrates) and 
three members in mammals [16, 17]. These data suggests that VRK and p53 protein 
families could have a parallel evolution. 
 
3. VRK1 expression is associated with proliferation phenotype in tumours 
 Any protein that might control cell division processes must be associated with 
the proliferation phenotype. Thus, if VRK1 is a candidate for such a role it must be 
expressed, probably at high levels, in proliferating cells. Several studies on VRK1 gene 
expression and protein levels in different systems indicate a potential role for VRK1 in 
cell proliferation. Initially high VRK1 RNA levels were detected in human tumour cells 
lines and normal tissues with high proliferation rates [18], and also in murine thymus 
and testis [19]. Also, during murine embryonic hematopoietic development, VRK1 
expression reached its peak at days E11.5 to E13.5, a time at which there is a massive 
embryonic cellular expansion [19]. In normal human epithelia, high VRK1 protein level 
was mostly detected in the transit amplifying compartment, colocalizing with p63 [2]. 
 VRK1 protein expression has also been determined in different human cancers. 
In head and neck squamous cell carcinomas (HNSCC), high VRK1 protein level 
positively correlated with several proliferation markers including Ki67, p63, CDK2, 
CDK6, cdc2, cyclin A, cyclin B1, topoisomerase II and survivin [20]. Lung cancers also 
have high VRK1 levels, which are more pronounced in those tumours with p53 
mutations [21].  In breast cancer, VRK1 is included within the sixteen-kinase gene 
expression signature reflecting a high mitotic activity, and which identifies luminal 
breast cancers with a poorer prognosis [22]. In human ER+ breast cancer, VRK1 
overexpression is also a predictor of poor response [23], and its downregulation is an 
indicator of a good outcome [24]. Tumour cell lines also express high levels of VRK1 
protein [21], and knock down of VRK1 results in a stop of  cell proliferation in tumour 
[25] and fibroblasts cell lines [2]. 
  
4. VRK1 gene is regulated in cell cycle and necessary for its progression 
  
 A protein coordinating cell division must be implicated in cell cycle entry. 
VRK1 is necessary for cell cycle entry [2].  In this context, VRK1 gene expression is 
turned off by serum withdrawal, resulting in a block in cell cycle progression, and 
serum readdition induces an immediate reexpression of the VRK1 gene [2]. VRK1 gene 
expression parallels that of MYC and FOS, behaving like an early gene [2] and 
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coincides with detectable expression of cyclin D1 gene (CCND1), and precedes that of 
cyclin  E (CCNE1) [2]. VRK1 knockdown results in loss of Rb phosphorylation [2], 
consistent with its early role in cell cycle progression. This early role is also supported 
by the identification of VRK1 protein within the transcriptional complex required for 
CCND1 gene expression by phosphorylation in Ser133 of the CREB transcription factor 
in  G1/S [3]. Changes in VRK1 protein level are also positively correlated with 
phospho-Rb, PCNA, and cyclinB1 and negatively with p27 [2]. Following serum 
withdrawal there is a drop of VRK1 and PCNA and an increase in p27 and 
dephosphorylated Rb levels [2]. Also Rb knockdown induces an increase of VRK1 gene 
expression [26], thus confirming the regulation of VRK1 in cell cycle progression. This 
early activation of VRK1 expression is detected as an increase in VRK1 protein levels 
as cell cycle progresses, which is higher at the S phase [5]. Furthermore, in cancers 
driven by mutation of KRAS, VRK1 and TBK1 are required for their progression [27]. 
Thus VRK1 can control cell cycle progression at an early stage, and might even have 
different roles depending on protein levels and activation in different cell cycle phases. 
 Certain stem cells have been proposed to follow a particular type of cell 
division, asymmetric division, that [28] generates two different daughter cells. One will 
remain with stem cell characteristics and the other will become a proliferating precursor 
that eventually will differentiate. VRK1 is upregulated in the embryonic stem and forms 
part of the asymmetric signature cell module that guides creation of epithelial cancer 
stem cells [29]. Also in salamander, an animal model for regeneration, expression of the 
VRK1 ortholog gene is upregulated during natural spinal cord regeneration [30]. 
 
5. VRK1 and DNA synthesis 
 The initiation of DNA synthesis is a key event in cell division, but the role of 
VRK1 on DNA in this process has not yet been directly addressed. However, there is 
some indirect evidence suggesting it might play an important role. In cell cycle, VRK1 
levels are higher in the S phase [5], and overexpression of human VRK1 induces an 
increase in the incorporation of bromodeoxyuridine into DNA, suggesting cells enter 
the S phase [3]. But these changes might be an indirect consequence of VRK1 
promotion of cell cycle progression, and not a consequence of a direct effect on DNA 
replication by itself. Also Vaccinia virus B1R protein, which has a 39 % identity and 
gave the name to the VRK protein family, is necessary for viral DNA replication, and 
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this viral function can be partially rescued by VRK1, and VRK2, in vaccinia viruses 
that are deficient in B1R function [31]. 
 
6. VRK1 and p53, the key player in protection against genetic damage  
  
Cells require precise safeguards mechanisms to protect them from DNA damage, 
which are required to guarantee fidelity in transmission of genetic information. The 
tumor suppressor p53 is a key player in the cellular response to stress and genotoxic 
damage, participating in cell cycle checkpoints [32-35]. The functions of p53 in 
response to DNA damage are regulated by phosphorylation of several residues in its N-
terminal transactivation domain and many kinases have been implicated in this 
regulation [36, 37]. VRK1 phosphorylates p53 uniquely in Thr18 [9, 25]. This Thr18 
residue forms a hydrogen bond with Asp21 that is necessary to maintain an hydrophobic 
side in the p53 alpha helix needed for interaction with its negative regulator mdm2 [38]. 
Disruption, by phosphorylation, of the p53 alpha helix destabilizes its structure and 
results in loss of binding to a hydrophobic pocket in mdm2 [38]. Thr18 is the key 
residue controlling the p53 switch from binding to mdm2 [39] to interaction with 
transcriptional cofactors [40, 41]. Phosphorylation in Thr18 switches p53 to a binding 
mode for transcriptional cofactors, and additional phosphorylations will modulate an 
increase in either specificity or affinity for one cofactor or another [40, 41] , thus 
determining the final specific biological effect, among the many responses triggered by 
an activated p53 [42, 43].  
 Normal cells must have a basal level of p53 that is ready to respond immediately 
to stimulation induced by cellular stress or DNA damage. This p53 stabilization is 
mediated by phosphorylation in Thr18 mediated by VRK1, this active phosphorylated 
p53 initiates an apoptotic or cell cycle stoppage response depending on additional 
signals received from other pathways [25], a phosphorylation mediated by other kinases 
in Ser15 and Ser20, that have a secondary role in the switch, these additional 
phosphorylations are critical for determining the selection and interaction of p53 with 
transcriptional cofactors [40]. But a stable accumulation of phosphorylated p53 will 
result in a permanent block, which will make a cell non viable or in cell death. Thus p53 
levels must be tightly regulated and should fluctuate depending on conditions. The p53 
stabilization has to be reversible and that is the role of mdm2, which downregulates p53 
by its ubiquitylation and subsequent degradation in the proteasome [44]. The 
requirement of mdm2 expression is a late event compared with the immediate 
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consequence of p53 phosphorylation, thus p53 must have oscillations in its level to 
permit repair without deleterious effects, which have been identified based on p53-
mdm2 pair [45, 46]. However, there are additional components in the regulatory 
process.  For example, p53 needs to be dephosphorylated to be able to interact with 
mdm2, but although some p53 phosphatases such as Wip1 [28] and PP1 [47] have been 
identified, they have not been fully studied and their integration in the temporal 
regulation of p53 remains to be completely understood. 
 VRK1 is a stabilizer of p53 by its Thr18 specific phosphorylation, but this 
phosphate has to be removed to permit p53 binding and ubiquitylation by mdm2, and 
one way is to remove its stabilizer. The p53 induced downregulation of VRK1 is 
indirect and does not affect VRK1 gene promoter or VRK1 ubiquitylation by mdm2 
[48]. Recent experiments have demonstrated that VRK1 is downregulated in a p53-
dependent manner in the autophagic pathway and protein degradation in the lysosome 
[48]. The accumulation of phosphorylated p53 induces the gene expression of DRAM 
[49]. DRAM is a small protein with four transmembrane domains and located in 
endosomes, lysosomes and other vesicles. DRAM is the likely mediator that targets 
VRK1 for lysosomal degradation. VRK1 degradation in lysosomes is eliminated by 
either knockdown of DRAM or of Beclin1, suggesting VRK1 is degraded by the 
autophagic pathway [50]. The removal of VRK1 permits p53 dephosphorylation, and 
thus p53 becomes accessible to mdm2 and subsequent degradation in the proteasome. 
Thus VRK1 and p53 can both be downregulated [48] relieving the block and preventing 
deleterious consequences of stable high levels of p53 (Fig.3). The VRK1-p53 relation 
appeared early in evolution; in C. elegans, also vrk-1 appears to regulate CEP-1(p53) 
controlling germ-cell proliferation [51]. 
 
7. VRK1 implication in the control of nuclear membrane dynamics 
 In mitosis, disassembly of the nuclear envelope is a process necessary to permit 
chromosome segregation into daughter cells and cell cycle progression. An important 
step in cell division is represented by the disassembly and reassembly of nuclear 
envelope, which is associated to chromatin condensation early in mitosis and after the 
end of chromosome segregation late in mitosis. Thus the nuclear membrane has a 
temporal and spatial regulation [52]. In this process BANF1 (barrier to autointegration 
factor 1) plays an important role. BANF1 is a small 10 kDa protein that forms dimers 
and interacts with DNA in a non-sequence specific manner [53]. BANF1 also binds to 
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proteins containing LEM domains, present in the inner nuclear membrane [54]; by this 
interaction BANF1 anchors DNA in interphase to the nuclear membrane and 
participates in chromatin remodelling complexes [52]. The effects of BANF1 are 
regulated by phosphorylation. VRK1 phosphorylates the N-terminal domain of BANF1 
in residues Ser4 or Thr2/Thr3, and VRK1 overexpression reduces BANF1 interaction 
with nuclear chromatin resulting in its dispersal and disassembly [4]. Phosphorylated 
BANF1 also has a reduced binding to DNA and LEM-containing proteins [4], 
delocalizing emerin and interfering with emerin binding to lamin A, both in mitosis and 
interphase [55]. The  phosphorylation of  BANF1 by VRK1 might be dependent on 
functional changes in the activity of VRK1, a kinase that is regulated during cell cycle 
in expression and activity, and required for G0 exit and G1 progression [2]. Also D. 
melanogaster NHK1 [56] and C. elegans Vrk-1 ortholog proteins [13] phosphorylated 
BANF1 and affect the structure of the nuclear membrane. Since the conservation among 
VRK1 proteins from three species is restricted to their kinase domain, BANF1 
phosphorylation by VRK1 was acquired as an early functional role in the evolution of 
this kinase.  
 
8. Regulation of VRK1 activity by interaction with the Ran small GTPase 
 The enzymatic activity of VRK1 can be regulated by different mechanisms that 
can affect either its kinase activity or its substrate specificity. These regulatory 
mechanisms include either protein interactions or covalent modifications. The first 
allosteric regulator of VRK proteins identified is the small GTPase Ran, which is the 
only nuclear member of the large small GTPase family [57]. Ran stably interacts with 
the three VRK proteins, but only the Ran interaction with VRK1 has been characterized 
[58]. Small GTPases have two alternative forms depending on the bound nucleotide; 
inactive or bound to GDP, and active or bound to GTP. Ran-GDP is mostly located in 
the cytosol and participates in the nuclear transport mechanism, kinetochore function 
[59], spindle assembly [60] and mitosis [61]; Ran-GTP, is located in the nucleus, and 
the nucleotide exchange from Ran-GDP to Ran-GTP is mediated by the nuclear GEF 
(Guanine exchange factor) RCC1 [62]. During mitosis Ran-GTP can form a 
concentration gradient, with the highest concentration near condensed chromosomes 
[61, 63]. If generation of Ran-GTP is blocked there is no formation of a mitotic spindle 
and chromosomes are misaligned [62].  Ran-GDP, but not Ran-GTP inhibits the kinase 
activity of VRK1 [58]. Although the full consequences of this VRK1 regulation are not 
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known, it has two clear effects. First, the active VRK1-Ran-GTP complex near 
chromosomes might facilitate phosphorylation of histones and chromatin condensation; 
and second the inactive VRK1-Ran-GDP complex might facilitate VRK1 nuclear 
transport and probably has additional roles not yet identified. 
 
9. Histone phosphorylation by VRK1 and chromatin condensation 
One of the initial events in mitosis after DNA replication is chromatin 
condensation which requires covalent modification of histones, particularly in the tail of 
H3 [64, 65]. Some histones are also substrates of VRK proteins. Drosophila 
melanogaster NHK1 (nucleosomal histone kinase) phosphorylates mitotic histones H2A 
which is required for acetylation of H3 [14, 66, 67], a phosphorylation also required for 
mitotic progression [15]. VRK1 contributes to chromatin condensation by 
phosphorylation of histone H3 [5, 58].  Human VRK1 directly phosphorylates histone 
H3 in Ser10 resulting in chromatin condensation, and cooperates with Aurora B, a 
process also required for progression of mitosis [5]. Ran-GTP binds to VRK1 without 
altering its activity, but Ran-GDP binding to VRK1 inhibits its kinase activity [58]. 
Since there is a nuclear gradient of Ran-GTP, this permits the formation of a nuclear 
gradient of VRK1 activity in the nucleus depending on its partner interactions. VRK1 
will be active near the chromosomes, where it can participate in chromatin condensation 
by phosphorylation of histone H3 [5], a phosphorylation that is lost by knocked-down 
of VRK1 [58]. Histone H3 can also be phosphorylated in Ser10 by Aurora B [68], and it 
is likely that VRK1 and Aurora B might be part of a common pathway not yet defined. 
In interphase, VRK1 colocalizes with heterochromatin and interacts with gamma 
heterochromatin protein 1 (HP1γ) [5]; while in a dividing cell, after chromatin 
condensation, VRK1 is not bound to chromosomes and appears dispersed with a 
granular aspect, where it might be participating in different signalling pathways not yet 
identified (Fig.2). Thus, VRK1 might have different roles in different phases of the cell 
cycle. 
  
10. VRK1 in Golgi fragmentation 
 In cell division cytoplasmic organelles also have to be distributed in daughter 
cells. But for unique organelles as the Golgi fragmentation in smaller vesicles is a 
necessary step during mitosis so that they can be  redistributed into daughter cells 
during the G2/M phase [69]. The regulation of Golgi fragmentation is not well known, 
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but mitogenic signals mediated by MAP kinases, particularly MEK1, induce Golgi 
fragmentation [70-72], representing an upstream component of the fragmentation 
pathway responding to a mitogenic signal. This mitogenic signal has a cytosolic 
branching point, in which downstream of MEK1 this fragmentation signal is mediated 
by Plk3 (Polo-like kinase 3) [73], a member of the Plk (polo-like kinase) protein family 
[74]. 
There is a subpopulation of VRK1 protein in the cytosol that colocalizes with 
several markers of the Golgi apparatus [12], such as giantin or GM130 [6]. This 
colocalization suggested that VRK1 might participate in processes regulating Golgi 
functions, and fragmentation in mitosis is a likely candidate. VRK1 has a consensus 
sequence for phosphorylation by Plk proteins and Plk3 phosphorylates VRK1 in Ser342 
within this sequence [6]. Mutation of this residue in VRK1, knocking-down VRK1, or 
the use of a catalytically inactive VRK1K179E,  all block Golgi fragmentation induced by 
both MEK1 and Plk3 [6]. Thus, one of the roles of the cytosolic VRK1 subpopulation 
late in G2 is to contribute to Golgi fragmentation in G2/M during mitosis [75, 76], and 
VRK1 is thus a new downstream step of this pathway in mitosis. In this process the 
situation of VRK1 downstream of MEK1-Plk3 permits that other signals mediated by 
MEK1 can only be transmitted to VRK1 at a time point when there is a significant level 
of VRK1 in the cytoplasm; thus the level of VRK1 expression and its subcelullar 
localization can contribute to the timing of specific events in cell division. 
 
11. Phenotypes associated to loss of VRK expression in vivo: defects in 
proliferation 
Initial studies reporting phenotypes due to mutation or loss of VRK proteins 
were made in model organisms and the consequences range from embryo lethality to 
sterility.  In D. melanogaster, a hypomorphic mutation in nhk-1 results in male and 
female sterility due to defective formation of the mitotic spindle in meiosis [77]. Other 
mutations in nhk-1 cause aberrant mitotic spindle in mitosis, and more severe nhk-1 
mutations are embryonic lethal [15]. In C. elegans, loss of vrk-1 by RNAi is also 
embryonic lethal, and there are failures in cell division affecting chromatin organization 
and mitotic spindle [78], as well as defects in nuclear pore formation [79]. In adults its 
silencing results in a slow growth phenotype [78]. Also Vrk-1 mutations in germinal 
cells result in inability to form gametes and sterility [80]. In C. elegans proliferation 
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defects in Vrk-1 can be rescue by CEP-1/p53, suggesting and early relationship between 
VRK1 and p53 [51].  
 In murine models, no viable knockout mice has been generated, but there are 
some data obtained in a hypomorphic gene trap knock-out model of murine VRK1, with 
a residual 15 % expression. There were described defects in gamete formation, affecting 
spermatogonia and oocyte formation, which lead to male and female sterility [81-83].  
In humans, a homozygous mutation affecting the nuclear localization signal of 
VRK1 causes a rare muscular atrophy syndrome with pontocerebellar hypoplasia, ataxia 
and muscular atrophy [84]. This rare mutation suggests that VRK1 might also have a 
role in neural development.  
These results suggest the importance of VRK1 in regulation of cell division and 
development, and it is likely than a knock-out model might be embryonic lethal. 
Conditional knock-out models addressing specific questions have not yet been reported.  
 
12. Is there a cell division coordinator role for VRK1? 
 All the evidence currently available points to a potential role for VRK1 in 
coordinating different processes required for cell division, although still many issues 
remain to be clarified. A protein that integrates signals coordinating the different 
biological processes needed for a successful cell division has to participate in all of 
these processes (Figure 3).  VRK1 is regulated in cell cycle, regulates p53, the main 
regulator of stress responses and DNA damage, participates in nuclear envelope 
assembly and disintegration, and Golgi fragmentation. If this coordinating role is real, 
VRK1 should also be activated by different types of stimuli that affect cell division, 
independently of their origin, thus all types of DNA damage should activate VRK1, as 
well as several growth factors that induce entry in cell cycle. However, additional 
components of the VRK1 system must be found in order to identify the response to the 
initiating signal, as well as downstream targets to connect with specific processes.  
Presumably the integration of VRK1 in macromolecular complexes would allow it to 
perform such a variety of functions and determine the specificity.  
 
 Current therapies in oncology are targeted at individual steps of processes 
require for the tumor cell, demanding the use of combination protocols with drugs 
targeting different proteins. An alternative would be to target a protein that can affect 
simultaneously several cellular processes, making it likely that the cell enter in a 
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catastrophic situation and become non-viable. Theoretically a coordinator protein might 
be a good candidate for therapeutic development applied to processes where 
proliferation plays an important role, particularly in the case of kinases for which it 
might be feasible to design specific inhibitors. Inhibition of VRK1 will target several of 
the hallmarks of the cancer phenotype [85]. For this reason VRK1 might be a suitable 
target for therapeutic development as divergences between VRK1 catalytic domain and 
the one of other kinases can facilitate the development of kinase-specific inhibitors [86, 
87], which might be helpful in cancer therapy, but this is something that needs further 
exploration. Also an increased understanding about VRK kinases biology and their 
mode of action would allow targeted therapies that interfere with its function in cancer 
cells without the possible physiological consequences of manipulating such a central 
signalling mediator.  
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FIGURE LEGENDS 
 
 
 
Figure 1. Potential cell division processes where VRK1 might play a regulatory role. 
 
Figure 2. Localization of human VRK1 in different stages of cell cycle progression in 
HeLa cells. In mitosis, VRK1 is not associated with condensed chromosomes. 
 
Figure 3. Double autoregulatory loop between VRK1, p53 and the p53-induced gene 
expression targets mdm2/hdm2 and DRAM. The activation of p53 by phosphorylation 
induces two genes, hdm2/mdm2 and DRAM, that contribute to downregulation of p53 
in the proteasome and of VRK1 in lysosomes. Based on Valbuena et al. [50] 
  
 
 
 
 
 
 
 
 
 
 
 
 
